Cost-effectiveness of photobiomodulation therapy for the prevention and management of cancer treatment toxicities: a systematic review

Autor(es):Mostrar menos -

Kauark-Fontes, Elisa ^[1] ; Rodrigues-Oliveira, Leticia ^[1] ; Epstein, Joel B. ^{[2, 3]} ; Faria, Karina Morais ^[4] ; Araujo, Anna Luiza Damaceno ^[1] ; Gueiros, Luiz Alcino Monteiro ^[5] ; Migliorati, Cesar Augusto ^[6] ; Salloum, Ramzi G. ^[7] ; Burton, Patricia ^[8] ; Carroll, James ^[8] ; Lopes, Marcio Ajudarte ^[1] ; Alves, Carolina Guimaraes Bonfim ^{[1, 4]} ; Palmier, Natalia Rangel ^[1] ; Prado-Ribeiro, Ana Carolina ^{[1, 4]} ; Brandao, Thais Bianca ^[4] ; Santos-Silva, Alan Roger ^[1]

Afiliação do(s) autor(es)

^[1] Univ Campinas UNICAMP, Piracicaba Dent Sch, Oral Diag Dept, Piracicaba, SP - Brazil

^[2] Cedars Sinai Hlth Syst, Los Angeles, CA - USA

^[3] City Hope Comprehens Canc Ctr, Duarte, CA - USA

^[4] Inst Canc Estado Sao Paulo ICESP, Dent Oncol Serv, Sao Paulo, SP - Brazil

^[5] Univ Fed Pernambuco, Clin & Prevent Dent Dept, Recife, PE - Brazil

^[6] Univ Florida, Coll Dent, Gainesville, FL - USA

^[7] Univ Florida, Coll Med, Gainesville, FL - USA

^[8] THOR Photomed Ltd, Chesham, Bucks - England

• Tipo de documento: Artigo de Revisão
• Fonte: SUPPORTIVE CARE IN CANCER; v. 29, n. 6 JAN 2021.
• Citações Web of Science: 0

Resumo

Purpose To identify and summarize the evidence on the cost-effectiveness of photobiomodulation (PBM) therapy for the prevention and treatment of cancer treatment-related toxicities. Methods This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE). Scopus, MEDLINE/PubMed, and Embase were searched electronically. Results A total of 1490 studies were identified, and after a two-step review, 4 articles met the inclusion criteria. The included studies analyzed the cost-effectiveness of PBM therapy used in the context of lymphedema for breast cancer and oral mucositis (OM) induced by chemotherapy and radiotherapy. Better outcomes were associated with PBM therapy. The incremental cost-effectiveness ratio ranged from 3050.75 USD to 5592.10 USD per grade 3-4 OM case prevented. PBM therapy cost 21.47 USD per percentage point reduction in lymphedema in comparison with 80.51 USD for manual lymph drainage and physical therapy. Conclusion There is limited evidence that PBM therapy is cost-effective in the prevention and treatment of specific cancer treatment-related toxicities, namely, OM and breast cancer-related lymphedema. Studies may have underreported the benefits due to a lack of a comprehensive cost evaluation. This suggests a wider acceptance of PBM therapy at cancer treatment centers, which has thus far been limited by the number of robust clinical studies that demonstrate cost-effectiveness for the prevention and treatment of toxicities. (AU)

• Processo FAPESP: 18/02233-6 - Segurança oncológica no uso da fotobiomodulação intraoral e extraoral em pacientes com carcinoma espinocelular de cavidade oral e orofaringe
• Beneficiário: Alan Roger dos Santos Silva
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 18/23479-3 - Segurança oncológica no uso da fotobiomodulação extraoral em pacientes com carcinoma espinocelular de cavidade oral e orofaringe
• Beneficiário: Elisa Kauark Fontes
• Modalidade de apoio: Bolsas no Brasil - Mestrado